In 2008 the Food and Drug Administration has revised approval process for new antidiabetic agents and introduced a requirement to demonstrate the cardiovascular safety in an international multicenter trial. Currently cardiovascular outcome trials of dipeptidyl peptidase-4 (DPP-4) inhibitors (SAVOR-TIMI53, EXAMINE and TECOS), sodium-glucose cotransporter 2 inhibitors (EMPAREG, CANVAS), glucagon-like peptide-1 receptor agonists (ELIXA, EXSCEL LEADER and SUSTAIN-6), ultralong-acting and insulin (DEVOTE) have been completed. The trials confirmed cardiovascular safety of these glucose-lowering medications, and in addition, EMPA-REG OUTCOME (empagliflozin), CANVAS (canagliflozin) and LEADER (liraglutide) have also demonstrated cardioprotective effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. These data led to the changes of clinical guidelines for the management of type 2 diabetes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.18087/cardio.2019.7.10267 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sitting time at work and cardiovascular disease risk-a longitudinal analysis of the Study on Mental Health at Work (S-MGA).
Int Arch Occup Environ Health
January 2025
Division of Work and Health, Federal Institute for Occupational Safety and Health (BAuA), Nöldnerstr. 40-42, 10317, Berlin, Germany.
Purpose: This study analyzed longitudinal data to examine whether occupational sitting time is associated with increases in body mass index (BMI) and five-year cardiovascular disease (CVD) risk.
Methods: We included 2,000 employed men and women (aged 31-60) from the German Study on Mental Health at Work (S-MGA) for a BMI analysis and 1,635 participants free of CVD at baseline (2011/2012) for a CVD analysis. Occupational sitting time was categorized into five groups (< 5, 5 to < 15, 15 to < 25, 25 to < 35, and ≥ 35 h per week).
Pathophysiological Effects on Coronary Arteries Following Radiofrequency Ablation: A Comprehensive Review.
Ann Noninvasive Electrocardiol
January 2025
Cardiovascular Analytics Group, Islamabad, Pakistan.
Radiofrequency ablation (RFA) is a safe and effective treatment for patients experiencing ventricular and atrial tachyarrhythmias. While complications after RFA are generally rare, the occurrence of coronary artery (CA) injury, albeit infrequent, can have significant clinical implications. Given the proximity of CAs to common ablation sites, understanding the interplay between RFA and CA perfusion pathophysiology is paramount.
View Article and Find Full Text PDFDrug-Coated Balloon-Based Treatment of Left Main True Bifurcation Lesion.
Catheter Cardiovasc Interv
January 2025
Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, South Korea.
Background: There is a paucity of data regarding drug-coated balloon (DCB) treatment in the context of left main (LM) true bifurcation lesions.
Aims: The aim of this study was to evaluate the safety and efficacy of DCB-based treatment for unprotected LM true bifurcation lesions.
Methods: A total of 39 patients with LM true bifurcation lesion (Medina: 1,1,1/0,1,1/1,0,1) who were successfully treated with DCB alone or in combination with drug-eluting stent (DES) were retrospectively enrolled into the DCB-based group.
Short-term effects of upstream high bolus dose of tirofiban in patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Coron Artery Dis
January 2025
Department of Cardiovascular Medicine, Assiut University Heart Hospital, Assiut, Egypt.
Background: No-reflow following primary percutaneous coronary intervention (PPCI) is challenging to treat.
Objectives: The objective of this study is to evaluate the efficacy and safety of upstream high-bolus-dose tirofiban administration in ST-segment elevation myocardial infarction (STEMI) cases undergoing PPCI on top of dual antiplatelet therapy, including ticagrelor, in comparison to selective bailout administration.
Methods: This hospital-based, randomized, single-blinded prospective interventional study was conducted on 150 patients at Assiut University Heart Hospital.
Comparison of ticagrelor and clopidogrel in primary percutaneous coronary intervention patients: a single-center retrospective study.
Coron Artery Dis
January 2025
Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China.
Background: It is uncertain whether ticagrelor is more effective and safer than clopidogrel in ST-segment elevation myocardial infarction (STEMI) patients in the East Asian population in the real world. This study compared the clinical outcomes of ticagrelor and clopidogrel in STEMI patients undergoing primary percutaneous coronary intervention (PCI).
Methods: We retrospectively enrolled 1124 patients diagnosed with STEMI in Nanjing First Hospital from July 2011 to April 2019.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!